Delivery Order SPE2DB22D3301-SPE2DB25FZ0AS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,735.09 to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Prolia 60 mg/ml syringes. This is a firm fixed price, non-set-aside contract with a completion date of September 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a competitive award under the company's existing pharmaceutical supply framework with the federal government. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 15, 2025, for Prolia 60 mg/mL syringes valued at $12,957.22. The contract employs firm fixed pricing with an ultimate completion date of September 16, 2025, and was competitively awarded without set-aside designation. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $67,829.29 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. This firm fixed-price delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $26,999.75 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Prolia 60 mg/ml syringes. This firm fixed price contract is non-competitive with no set-aside designation and is scheduled for completion by August 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, valued at $9,104.04 under firm fixed price terms. The award, issued on August 7, 2025, with completion targeted for August 8, 2025, represents a child delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $35,094.09 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed-price delivery order represents a competitively awarded non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $14,539.96 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 8, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with...
- The Defense Logistics Agency awarded a $10,746.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Prolia 60 mg/ml syringes. The contract, designated as a non-set-aside competitive award, is scheduled for ultimate completion by April 23, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,723.10 by the Defense Logistics Agency on August 5, 2025, for the supply of Prolia 60 mg/ml syringes. The contract utilizes firm fixed price terms and carries an ultimate completion date of August 6, 2025. This award is unset-aside and was competitively awarded through the federal procurement process. The delivery order will be fulfilled from the vendor's Corporate Office...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Prolia 60 mg/ml syringes. This competitive, firm fixed-price delivery order has a ceiling value of $10,714.50 and an ultimate completion date of September 16, 2025. The contract was placed with AmerisourceBergen's Corporate Office division located in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0ASDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Prolia 60 mg/mL syringes, valued at $11,629.70. This is a firm fixed price delivery order with an ultimate completion date of August 27, 2025, and represents a non-set-aside competitive award. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's existing relationship with DLA for pharmaceutical supply. This award is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. AmerisourceBergen is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The company's extensive contract portfolio with DLA demonstrates its capability to deliver a comprehensive range of pharmaceutical products, medical supplies, and specialty medications across multiple therapeutic domains to support the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 8/26/25 |